Trince is a spin-off of Ghent University advancing the LumiPore transfection platform, which uses laser exposure and photothermal nanoparticles to transiently permeabilize the cellular plasma membrane. The platform is designed to deliver a wide variety of effector molecules (nucleic acids or proteins) into virtually any cell type, including hard‑to‑transfect cells such as immune cells used in cell therapies. The technology stems from a decade of research by Kevin Braeckmans and Stefaan De Smedt and is covered by a portfolio of pending patents; the related intellectual property will be transferred to Trince. The company plans to focus initially on two products: a laser‑based research device combined with proprietary nanoparticles, and a modified, fiber‑encapsulated version that avoids direct nanoparticle–cell contact for safe translation into therapeutic cell production. Led by CEO Philip Mathuis and CSO Kevin Braeckmans, Trince intends to use the funds to expand its development efforts and advance both research and manufacturing applications.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2021